Trials / Completed
CompletedNCT04206293
A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite Injection on Healthy Volunteers
Prospective, Open-Label Study, to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite Injection on Healthy Volunteers
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 30 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the impact on skin quality attributes, including physical measurements and gene and protein expression (histological and genomic analysis), following administration of Juvéderm® VOLITE in the volar forearms of healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Juvederm® VOLITE | 1 mL of Juvéderm® VOLITE contains hyaluronic acid gel 12.0 milligram (mg), lidocaine hydrochloride 3.0 mg in a phosphate buffer pH 7.2 q.s. 1 mL (or gram). |
Timeline
- Start date
- 2019-10-08
- Primary completion
- 2020-07-29
- Completion
- 2020-07-29
- First posted
- 2019-12-20
- Last updated
- 2021-08-26
- Results posted
- 2021-08-26
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT04206293. Inclusion in this directory is not an endorsement.